Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Cancer

Volumn 113, Issue 11, 2008, Pages 3242-3247

  Qualman, Stephen ^a   Lynch, James ^b   Bridge, Julia ^c   Parham, David ^d   Teot, Lisa ^e   Meyer, William ^d   Pappo, Alberto ^f  

^a Center for Childhood Cancer   (United States)

^b UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f TEXAS CHILDREN S CANCER CENTER   (United States)

Author keywords

Anaplasia; Incidence; Prognostic significance; Rhabdomyosarcoma; Soft tissue sarcoma

Indexed keywords

ANAPLASTIC CARCINOMA; ARTICLE; CHILD; EMBRYONAL RHABDOMYOSARCOMA; FEMALE; HUMAN; INFANT; MALE; PATHOLOGY; PRESCHOOL CHILD; PREVALENCE; PROSPECTIVE STUDY; RHABDOMYOSARCOMA; SARCOMA; SURVIVAL;

ANAPLASIA; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; PREVALENCE; PROSPECTIVE STUDIES; RHABDOMYOSARCOMA; RHABDOMYOSARCOMA, EMBRYONAL; SARCOMA; SURVIVAL ANALYSIS;

EID: 58149383535     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23929     Document Type: Article

References (29)

1. Ries LA, Smith M, Gurney JG, et al. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. SEER Program Pub. No. 99-4649. Bethesda, MD: National Cancer Institute; 1999.
2. Qualman SJ, Bowen J, Parham DM, et al. Protocol for the examination of specimens from patients (children and young adults) with rhabdomyosarcoma. Arch Pathol Lab Med. 2003;127:1290-1297. (Pubitemid 37248325)
3. Raney RB, Anderson JR, Barr FG, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first 2 decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol. 2001;23:215-220. (Pubitemid 32524925)
4. Qualman SJ, Coffin CM, Newton WA, et al. Intergroup Rhabdomyosarcoma Study: update for pathologists. Pediatr Dev Pathol. 1998;1:550-561. (Pubitemid 128542175)
5. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001;19:3091-3102. (Pubitemid 32567502)
6. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995;13:610-630.
7. Maurer HM, Gehan EA, Beltangady M, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer. 1993;71:1904-1922. (Pubitemid 23067412)
8. Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer. 1988;61:209-220. (Pubitemid 18056471)
9. Pappo AS, Lyden E, Breitfeld P, et al. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. J Clin Oncol. 2007;25:362-369. (Pubitemid 350002984)
10. Meza JL, Anderson J, Pappo AS, et al. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol. 2006;24:3844-3851. (Pubitemid 46630730)
11. Palmer NFM. Histopathology and prognosis in the second Intergroup Rhabdomyosarcoma Study (IRS II). Proc Am Soc Clin Oncol. 1983;2:229.
12. Palmer NS, Foulkes M. Histology and prognosis in rhabdomyosarcoma (IRS-I). Proc Am Soc Clin Oncol. 1982;1:170.
13. Faria P, Beckwith JB, Mishra K, et al. Focal versus diffuse anaplasia in Wilms tumor - new definitions with prognostic significance: a report from the National Wilms Tumor Study Group. Am J Surg Pathol. 1996;20:909-920. (Pubitemid 26250632)
14. Kodet R, Newton WA Jr, Hamoudi AB, et al. Childhood rhabdomyosarcoma with anaplastic (pleomorphic) features. A report of the Intergroup Rhabdomyosarcoma Study. Am J Surg Pathol. 1993;17:443-453. (Pubitemid 23121774)
15. Newton WA Jr, Gehan EA, Webber BL, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification - an Intergroup Rhabdomyosarcoma Study. Cancer. 1995;76:1073-1085.
16. Lawrence W Jr, Anderson JR, Gehan EA, et al. Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children's Cancer Study Group. Pediatric Oncology Group. Cancer. 1997;80:1165-1170. (Pubitemid 27427618)
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
18. Cox DR. Regression models and life tables (with discussion). J R Stat Soc (B). 1972;74:187-220.
19. International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995.
20. Gajjar A, Hernan R, Kocak M, et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol. 2004;22:984-993. (Pubitemid 41095029)
21. Dome JS, Cotton CA, Perlman EJ, et al. Treatment of anaplastic histology Wilms' tumor: results from the Fifth National Wilms' Tumor Study. J Clin Oncol. 2006;24:2352-2358. (Pubitemid 46630667)
22. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7:813-820. (Pubitemid 44464063)
23. Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer. 2002;94:552-560. (Pubitemid 34081387)
24. Frank AJ, Hernan R, Hollander A, et al. The TP53-ARF tumor suppressor pathway is frequently disrupted in large/ cell anaplastic medulloblastoma. Brain Res Mol Brain Res. 2004;121:137-140. (Pubitemid 38224178)
25. Lahoti C, Thorner P, Malkin D, et al. Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome. Am J Pathol. 1996;148:1577-1589. (Pubitemid 26135898)
26. Bardeesy N, Falkoff D, Petruzzi MJ, et al. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet. 1994;7:91-97.
27. Stewenius Y, Jin Y, Ora I, et al. Defective chromosome segregation and telomere dysfunction in aggressive Wilms' tumors. Clin Cancer Res. 2007;13:6593-6602. (Pubitemid 350206793)
28. Bridge JA, Liu J, Qualman SJ, et al. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. Genes Chromosomes Cancer. 2002;33:310-321. (Pubitemid 34130938)
29. Cam H, Griesmann H, Beitzinger M, et al. p53 family members in myogenic differentiation and rhabdomyosarcoma development. Cancer Cell. 2006;10:281-293. (Pubitemid 44512191)